Gallo RC. History of the discoveries of the first human retroviruses:

HTLV-I and HTLV-II. Oncogene 2005; 24:5926-30. Epub

2005/09/13.

2. Yamashiro T, Kamiya H, Miyara T, Gibo S, Ogawa K, Akamine T,

et

al.

CT scans of the chest in carriers of human T-cell lymphotropic

virus type 1: presence of interstitial pneumonia. Acad Radiol

2012; 19:952-957. Epub 2012/05/15.

3. Naderi M, Paryan M, Azadmanesh K, Rafatpanah H, Rezvan H,

Mirab Samiee S. Design and development of a quantitative

real time PCR assay for monitoring of HTLV-I provirus in whole

blood. Journal of clinical virology : the official publication of the

Pan American Society for Clinical Virology. 2012; 53:302-307. Epub

2012/02/07.

4. Trevino A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM,

et al.

Trends in the prevalence and distribution of HTLV-I and HTLV-II

infections in Spain. Virol J 2012; 9:71. Epub 2012/03/27.

5. Sadeghian MH, Keramati MR, Ayatollahi H, Feizabadi AS, Tehranaian

F, Shakibyee H. Is there any relationship between expressions

of minor blood group antigens with HTLV-I infection?

Transfusion and apheresis science : official journal of the World

Apheresis Association : official journal of the European Society

for Haemapheresis. Transfus Apher Sci 2012; 47:151-154. Epub

2012/08/04.

6. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F,

Bidkhori HR, Shamsian SK, Ahmadi S,

et al.

High prevalence of

HTLV-I infection in Mashhad, Northeast Iran: a population-based

seroepidemiology survey. Journal of clinical virology : the official

publication of the Pan American Society for Clinical Virology.

J Clin Virol 2011; 52:172-176. Epub 2011/08/16.

7. Azarpazhooh MR HK, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-

Moghaddam MR, Valizadeh N

, et al

. Human T-lymphotropic

virus type 1 prevalence in northeastern Iran, Sabzevar: an

epidemiologic-based study and phylogenetic analysis. AIDS Res

Hum Retroviruses 2012; 28:1095-10101.

8. Saito M. Immunogenetics and the Pathological Mechanisms

of Human T-Cell Leukemia VirusType 1- (HTLV-I-)Associated Myelopathy/

Tropical Spastic Paraparesis (HAM/TSP). Interdiscip Perspect

Infect Dis 2010; 2010:478461. Epub 2010/02/20.

9. Abdelbary NH, Abdullah HM, Matsuzaki T, Hayashi D, Tanaka

Y, Takashima H,

et al.

Reduced Tim-3 expression on human Tlymphotropic

virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes

in HTLV-I infection. J Infect Dis 2011; 203:948-959. Epub

2011/03/16.

10. Cabrera ME, Labra S, Catovsky D, Ford AM, Colman SM, Greaves

MF,

et al.

HTLV-I positive adult T-cell leukaemia/lymphoma (ATLL)

in Chile. Leukemia 1994; 8:1763-1767. Epub 1994/10.01/

11. Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S,

et al

. Phase II study on combination therapy with CHOP-Zenapax

for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).

Leukemia Res 2012; 36:857-861. Epub 2012/01/03.

12. Kokoris SI, Siakantaris MP, Kontopidou FN, Kyrtsonis MC, Tsakris

A, Spanakis N,

et al.

Adult T-cell leukemia/lymphoma (ATLL): report

of two fully documented Hellenic patients. Leukemia Lymphoma

2004; 45:715-21. Epub 2004/05/27.

13. Costa DT, Sundberg M, Passos L, Muniz AL, Santos S. Interferon

Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and

Modifies the Immune Response in a Patient with HAM/TSP. Case

Rep Neurol Med 2012; 2012:958786. Epub 2012/09/07.

14. Cabral F ,Arruda LB, de Araujo ML, Montanheiro P, Smid J, de

Oliveira AC,

et al.

Detection of human T-cell lymphotropic virus

type 1 in plasma samples. Virus Res 2012; 163:87-90. Epub

2011/09/20.

15. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr

L,

et al.

The impact of interferon-alpha treatment on clinical

and immunovirological aspects of HTLV-I-associated myelopathy

in northeast of Iran. J Neuroimmunol 2012; 250:87-93. Epub

2012/06/26.

16. Currer R, Van Duyne R, Jaworski E, Guendel I, Sampey G, Das R,

et al

. HTLV tax: a fascinating multifunctional co-regulator of

viral and cellular pathways. Front Microbiol 2012; 3:406. Epub

2012/12/12.

17. Leal FE, Ndhlovu LC, Hasenkrug AM, Bruno FR, Carvalho KI,

Wynn-Williams H,

et al

. Expansion in CD39(+) CD4(+) Immunoregulatory

T Cells and Rarity of Th17 Cells in HTLV-I Infected Patients

Is Associated with Neurological Complications. PLoS Negl

Trop Dis 2013; 7:e2028. Epub 2013/02/15.

18. Yamano Y, Sato T .Clinical pathophysiology of human T-lymphotropic

virus-type 1-associated myelopathy/tropical spastic para

219

HTLV-I proviral load in ATL, HAM-TSP and healthy carriers Akbarin MM R et al

Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013

paresis. Front Microbiol 2012; 3:389. Epub 2012/11/20.

19. Tsukasaki K, Imaizumi Y, Tawara M, Fujimoto T, Fukushima T,

Hata T,

et al

. Diversity of leukaemic cell morphology in ATL correlates

with prognostic factors, aberrant immunophenotype and

defective HTLV-I genotype. Br J Haematol 1999; 105:369-375. Epub

1999/05/08.

20. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A ,Uchimaru K,

Koh KR,

et al

. Human T-cell leukemia virus type I (HTLV-I) proviral

load and disease progression in asymptomatic HTLV-I carriers: a

nationwide prospective study in Japan. Blood 2010; 116:1211-1219.

Epub 2010/05/08.

21. Taylor GP TJ, Matutes E. Prospective study of HTLV-I infection in

an initially asymptomatic cohort. J Acquir Immune Defic Syndr

1999; 22:92-100.

22. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi

M,

et al.

Phase 2 study of the efficacy and safety of the combination

of arsenic trioxide, interferon alpha, and zidovudine in

newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

Blood 2009; 113:6528-6532. Epub 2009/05/05.

23. Nasr R, El Hajj H, Kfoury Y, de The H, Hermine O, Bazarbachi A.

Controversies in targeted therapy of adult T cell leukemia/lymphoma:

ON target or OFF target effects? Viruses 2011; 3:750-769.

Epub 2011/10/14.

24. Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematopathol

2010 .25-50:9 ;Epub 2010/05/28.

25. Nagai M UK, Matsumoto W, Kodama D, Takenouchi N, Moritoyo

T. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and

243 asymptomatic HTLV-I carriers: high proviral load strongly

predisposes to HAM/TSP. J Neurovirol 1998; 4:586-593.

26. Adaui V, Verdonck K, Best I, Gonzalez E, Tipismana M, Arevalo J,

et al.

SYBR Green-based quantitation of human T-lymphotropic

virus type 1 proviral load in Peruvian patients with neurological

disease and asymptomatic carriers: influence of clinical status,

sex ,and familial relatedness. J Neurovirol 2006; 12:456-465. Epub

2006/12/13.

27. Montanheiro P, Olah I, Fukumori LM, Smid J, Oliveira AC, Kanzaki

LI,

et al.

Low DNA HTLV-II proviral load among women in Sao Paulo